Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 8/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | GRK5 | P34947 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4478994 | 0.89 | SLC2A1 (0.55) | DAOSLC2A1DPP4TAAR1BACE1 | |
| SCHEMBL4480633 | 0.89 | DAO (0.49) | DAOSLC2A1DPP8 | |
| SCHEMBL5096521 | 0.85 | DAO (0.52) | DAOSLC2A1DPP4TAAR1MAPT | |
| SCHEMBL4468891 | 0.82 | SLC2A1 (0.51) | SLC2A1MAPT | |
| SCHEMBL4492022 | 0.81 | MAPT (0.41) | SLC2A1MAPTRAB9A | |
| SCHEMBL4481366 | 0.77 | SLC2A1 (0.56) | DAOSLC2A1DPP4DPP8RAB9A | |
| SCHEMBL4565035 | 0.76 | TNKS (0.39) | DAOSLC2A1MAPTRAB9A | |
| SCHEMBL4472776 | 0.75 | BIRC5 (0.38) | DAOSLC2A1MAPT | |
| SCHEMBL4491224 | 0.75 | DAO (0.34) | DAOSLC2A1MAPT | |
| SCHEMBL4485647 | 0.74 | HSD11B1 (0.35) | DAOSLC2A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579353-B2 | Pyridinone derivatives against malaria | GLAXO GROUP LIMITED (GB) | 2009-08-25 | — | — | US | claimed |
| US-20080287461-A1 | Pyridinone Derivatives Against Malaria | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | claimed |
| US-7579353-B2 | Pyridinone derivatives against malaria | GLAXO GROUP LIMITED (GB) | 2009-08-25 | — | — | US | disclosed |
| US-20080287461-A1 | Pyridinone Derivatives Against Malaria | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| EP-1858876-A2 | PYRIDINONE DERIVATIVES AGAINST MALARIA | GLAXO GROUP LIMITED (GB) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006094799-A2 | PYRIDINONE DERIVATIVES AGAINST MALARIA | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287461-A1 | Pyridinone Derivatives Against Malaria | G6PD, PNPO, PLPBP | DAO 2428/4885SLC2A1 2278/4885DPP4 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.